REG - GSK PLC - Directorate Change

GSKAnnouncement

29/02/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240229:nRSc8660Ea&default-theme=true

RNS Number : 8660E  GSK PLC  29 February 2024

Issued: 29 February 2024, London UK

 

GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director

 

 

 

GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has been
appointed to the Board of the Company as a Non-Executive Director. Jeannie
will join the Board on 4 March 2024.

 

Jeannie is currently the Phillip A. Sharp, PhD, Endowed Chair in Molecular
Biology and Acting Chair of the Department of Molecular Biology at the
Massachusetts General Hospital. She is also Professor of Genetics (and
Pathology) at Harvard Medical School. She is a pioneer in the field of RNA
Biology and its application to drug development and therapeutics. In addition
to senior leadership positions held at both Harvard Medical School and the
Massachusetts General Hospital, Jeannie co-founded Translate Bio and Fulcrum
Therapeutics, two biotech companies specialising in RNA and epigenetic
therapies.

 

Jeannie is a Member of the National Academy of Sciences, the National Academy
of Medicine, a Harrington Rare Disease Scholar of the Harrington Discovery
Institute, a recipient of the Lurie Prize from the Foundation for the National
Institutes of Health, an awardee of the Centennial Prize from the Genetics
Society of America, the 2010 Molecular Biology Prize and the 2020 Cozzarelli
Prize from the National Academy of Sciences, U.S.A, and a Fellow of the
American Association for the Advancement of Science. She has also served on
the Board of the Genetics Society of America.

 

Commenting on the appointment, Sir Jonathan Symonds, Chair of GSK said, "I am
delighted to welcome Jeannie to GSK. Her deep expertise in scientific and
medical innovation, including in the field of RNA biology and epigenetics
which are key parts of GSK's R&D approach, together with her experience in
public health, will bring strong additional perspective to the Board."

 

 

Notes:

 

   1.   The appointment of Dr Lee was made by the Board on the recommendation
   of the Nominations & Corporate Governance Committee. The Committee
   conducted an extensive search and selection process for this appointment,
   using an external search firm, which is a signatory of the Voluntary Code of
   Conduct for Executive Search Firms. The external search firm provided a
   diverse list of candidates who were approached, evaluated and interviewed
   against an agreed set of criteria aligned to the Board's target skills matrix.
   The Board satisfied itself that Dr Lee had the experience and time available
   to carry out the role.

   2.   The Board has determined that Dr Lee is an independent Non-Executive
   Director in accordance with the UK Corporate Governance Code.

   3.   Dr Lee will receive the standard basic fee for a Non-Executive Director
   of £118,352 per annum (including travel allowance). She will also receive
   fees of £30,000 per annum as a scientific and medical expert. Dr Lee will be
   required to build towards a share ownership requirement of GSK shares in
   accordance with the Company's shareholder approved Non-Executive remuneration
   policy.

   4.   "Scientific and Medical Expert" - The Board designates Non-Executive
   Directors whose expertise or backgrounds as renowned medical scientists,
   researchers, or physicians mean that they can bring scientific or industry
   expertise to the Board's deliberations.

   5.   Dr Lee will become a member of the Science and Corporate Responsibility
   committees on her appointment.

   6.   Dr Lee does not have a service contract. She has a letter of
   appointment which may be viewed by contacting the Company Secretary at the
   Company's registered office.

   7.   There are no further disclosures to be made in respect of Dr Lee's
   appointment under Listing Rule 9.6.13R.

   8.   As of 4 March 2024, the Board of GSK will comprise:

Sir Jonathan Symonds      Non-Executive Chair
   Emma Walmsley             Chief Executive Officer
   Julie Brown               Chief Financial Officer
   Charles Bancroft          Senior Independent Non-Executive Director
   Elizabeth McKee Anderson  Independent Non-Executive Director
   Dr Hal Barron             Non-Executive Director
   Dr Anne Beal              Independent Non-Executive Director
   Wendy Becker              Independent Non-Executive Director
   Dr Hal Dietz              Independent Non-Executive Director
   Dr Jesse Goodman          Independent Non-Executive Director
   Dr Jeannie Lee            Independent Non-Executive Director
   Urs Rohner                Independent Non-Executive Director
   Dr Vishal Sikka           Independent Non-Executive Director

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 

 GSK enquiries
 Media:               Tim Foley             +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn        +1 202 603 5003       (Washington DC)

 Investor Relations:  Nick Stone            +44 (0) 7717 618834   (London)
                      James Dodwell         +44 (0) 20 8047 2406  (London)
                      Mick Readey           +44 (0) 7990 339653   (London)
                      Josh Williams         +44 (0) 7385 415719   (London)
                      Camilla Campbell      +44 (0) 7803 050238   (London)
                      Steph Mountifield     +44 (0) 7796 707505   (London)
                      Jeff McLaughlin       +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco      +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in the company's Annual Report on Form 20-F for 2022,
and Q4 Results for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKVLFLZLLBBBK